{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"comment":"No MTD found","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Determine the maximum tolerated dose (MTD)","groups":[{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG000","title":"Dose Regimen A (DR-A) Escalation"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG001","title":"Dose Regimen B (DR-B) Escalation"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle in DR-A is 28 days, DR-B and DR-C is 21 days), an average of 138 Days","title":"Determine the Maximum Tolerated Dose (MTD) of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas","type":"PRIMARY","unitOfMeasure":"mg/kg"}